With a pipeline based on sound proof-of-principle, 4SC is building an independent strategy focussed on orphan drugs with best-in-class blockbusters exploited through major partners. The company's lead product resminostat is in a pivotal trial as a much needed maintenance therapy in the orphan CTCL (Cutaneous T-Cell Lymphoma). Class I HDACi (Histone Deacetylase inhibitors) are showing real promise in combination with the new wave of immuno-therapeutics. Entering phase II in combination with an
11 Dec 2017
Orphan to best-in-class: HDACi come of age
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Orphan to best-in-class: HDACi come of age
4SC AG (VSC:FRA) | 0 0 4.2% | Mkt Cap: 249.2m
- Published:
11 Dec 2017 -
Author:
Chris Redhead -
Pages:
38
With a pipeline based on sound proof-of-principle, 4SC is building an independent strategy focussed on orphan drugs with best-in-class blockbusters exploited through major partners. The company's lead product resminostat is in a pivotal trial as a much needed maintenance therapy in the orphan CTCL (Cutaneous T-Cell Lymphoma). Class I HDACi (Histone Deacetylase inhibitors) are showing real promise in combination with the new wave of immuno-therapeutics. Entering phase II in combination with an